Format

Send to

Choose Destination
Front Oncol. 2014 Jul 22;4:176. doi: 10.3389/fonc.2014.00176. eCollection 2014.

Pediatric medulloblastoma - update on molecular classification driving targeted therapies.

Author information

1
Neurosurgery, King's College Hospital London , London , UK.
2
Royal Bolton Hospital , Bolton , UK.
3
BMT/Oncology, University of Bristol , Bristol , UK.
4
Brain Tumour Group, Institute of Clinical Neuroscience, University of Bristol , Bristol , UK.

Abstract

As advances in the molecular and genetic profiling of pediatric medulloblastoma evolve, associations with prognosis and treatment are found (prognostic and predictive biomarkers) and research is directed at molecular therapies. Medulloblastoma typically affects young patients, where the implications of any treatment on the developing brain must be carefully considered. The aim of this article is to provide a clear comprehensible update on the role molecular profiling and subgroups in pediatric medulloblastoma as it is likely to contribute significantly toward prognostication. Knowledge of this classification is of particular interest because there are new molecular therapies targeting the Shh subgroup of medulloblastomas.

KEYWORDS:

classification; medulloblastoma; molecular; pediatric; therapies

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center